ヒトパピローマウイルス(HPV)感染症治療薬の世界市場・治験インサイト

Kuick Researchが発行した調査報告書(DATA7100521)
◆英語タイトル:Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023
◆商品コード:DATA7100521
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2017年9月
◆ページ数:220
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,800 ⇒換算¥203,400見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥406,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Kuick Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

“Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on the ongoing market and clinical development in HPV drug market. Report highlights the trends in the global HPV drug market and gives detailed overview on the HPV drug clinical pipeline by phase, drug class and mode of action. As per report findings, there are 9 HPV drugs commercially available in the market and 78 drugs are in multiple phases of clinical pipeline. Majority of the HPV drugs are in Preclinical phase of development followed by Phase-II clinical trials.
In the past decade, there have been remarkable advances in the understanding of the natural history of human papillomavirus (HPV) infection and its role as the major risk factor in the development of cervical and other anogenital cancers, which has led to increased research and development in the HPV drug segment; thus leading to the introduction of excellent and promising therapeutics in the Human Papilloma virus drug segment.

Among the various therapeutics currently available for Human Papilloma virus infection, is the Human Papilloma Virus Vaccine which is currently the dominant form of medication in the HPV therapeutic segment. These Vaccines are considered to be the most superior kinds of therapeutics due to their ability to provide long term protection from Human Papilloma Virus. Apart from being safe and effective, these have been in wide use in the vaccination of preteen girls and boys in US and other developed countries to ensure their long term protection and prevention from exposure to the Human Papilloma virus.

Further, these vaccines also ensure high efficacy in preventing genital warts, anal cancer, cervical cancer, vulvar cancer and vaginal cancer which are widely known to be caused by certain types of human papilloma virus. It has also been used in the prevention of lesions that are caused by the Human Papilloma virus which can lead to the above mentioned complications.

“Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023” Report Highlights:

• Global Human Papillomavirus Infection Market Analysis
• Global Human Papillomavirus Infection Drug Market Dynamics
• Clinical Insight on Approved Drugs for Treating Human Papillomavirus Infection
• Global Human papillomavirus Infections Drug Clinical Pipeline by Company & Phase
• Global Human Papillomavirus Infection Drug Market Future Perspective

The next decade in research against HPV infections should be geared up to fill in gap in knowledge of HPV gene expression and its regulation. The future treatment approaches is coupled with application of next generation sequencing and proteomic technologies, screening of new, more extensive small molecule libraries to look for molecule inhibitory to either the virus replication cycle or to tumor formation. The RNA based therapies should advance the prospects of new anti-HPV treatments to improve the disease.

The increase in understanding of new drugs, development of new adjuvants along with increasing funding from private and public sector will drive the growth of HPV infection drug market in near future. It is expected that there will be more efforts involved in the R&D and commercialization of therapeutic HPV vaccines driven by the increasing prevalence of HPV associated malignancies across the globe.

【レポートの目次】

1. Introduction to Human Papillomavirus Infection
1.1 Overview
1.2 Pathogenicity & Diversity of Human Papillomavirus
1.2.1 Alpha Papillomaviruses
1.2.2 Beta Papillomaviruses
1.2.3 Gamma Papillomaviruses

2. Pathophysiology of Human Papillomavirus
2.1 Life Cycle of Human Papillomavirus
2.1.1 Primary Infection of Epidermis Layer
2.1.2 Genome Maintenance
2.1.3 Proliferative Phase
2.1.4 Viral Genome Amplification
2.1.5 Virus Assembly & Release
2.2 Molecular Mechanism of Human Papillomavirus to Induce Disease

3. Response of Immune System Against Human Papillomavirus
3.1 Innate Immunity
3.2 Adaptive Immunity

4. Clinical Management Strategies Against Human Papillomavirus Infection
4.1 Vaccination Approach for Human Papillomavirus
4.2 Therapeutic Drugs Targets
4.2.1 Interferon
4.2.2 RNA Interference based Therapies
4.2.3 Natural or Herbal Derivatives

5. Emerging Therapies for Treatment of Infection
5.1 Live Vector based Vaccines
5.2 Protein or Peptide based Vaccines
5.3 Nucleic Acid based Vaccines
5.4 Whole Cell based Vaccines

6. Approved Drugs for Treating Human Papillomavirus Infection: Clinical, Drug Class & Patent Insight
6.1 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)
6.2 Interferon alpha-2b (Intron A, Viraferon & Virtron)
6.3 Tretinoin (Acnisdin Retinoico, Avita, Dermojuventus, Loderm Retinoico, Retirides,
Vesanoid, Vitamin-A Acid & Vitanol)
6.4 Imiquimod (Aldara, Beselna Cream 5%, Vyloma & Zyclara)
6.5 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix)
6.6 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
6.7 Interferon-alpha-n3 (Alferon LDO, Alferon N, Alferon N Gel, Alferon N Injection,
Alferon N LDO, Altemol & Naturaferon)
6.8 Polyphenon E (Polyphenon E & Veregen)
6.9 Interferon Gamma Biosimilar (Ingaron)

7. Global Human Papillomavirus Infection Market Analysis
7.1 Introduction to Infectious Disease Market
7.2 Global Human Papillomavirus Market Analysis

8. Global Human Papillomavirus Infection Drug Market Dynamics
8.1 Favorable Parameters
8.2 Challenges to Market Growth

9. Global Human Papillomavirus Infection Drug Market Future Perspective

10. Global Human papillomavirus Infections Drug Clinical Pipeline by Company & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III

11. Competitive Landscape
11.1 3M Pharmaceuticals
11.2 Aclaris Therapeutics
11.3 Mylan Pharmaceuticals
11.4 Biogen Idec
11.5 Cutanea Life Sciences
11.6 Hemispherx
11.7 Inovio Pharmaceuticals
11.8 ISA Pharmaceuticals
11.9 Lees Pharmaceutical Holdings
11.10 MedImmune
11.11 Merck
11.12 Nielsen BioSciences
11.13 Novan

Figure 1-1: Structural Components of Viral Particles
Figure 1-2: Fundamental Constituents of Human Papillomavirus
Figure 1-3: Classification & Diversity of Human Papillomavirus
Figure 2-1: Life Cycle of Human Papillomavirus to Cause the Infection
Figure 2-2: Multistep Model of Cancer Development by Human Papillomavirus
Figure 3-1: HPV Infection Model & Activation of Innate Immune Response
Figure 3-2: Adaptive Immune Response to Human Papillomavirus Infection
Figure 4-1: Clinical Management Strategies for Treating Human Papillomavirus Infections
Figure 4-2: HPV L1 VLP Vaccine Mechanism of Action
Figure 4-3: Response of Interferons with Human Papillomavirus
Figure 7-1: Global – Infectious Disease Diagnostic Market Growth Estimation (US$ Million), 2016-2023
Figure 7-2: Global Infectious Therapeutics Market Growth (US$ Billion), 2016-2023
Figure 7-3: Global Viral Infections Market Growth Estimation (US$ Billion), 2016-2023
Figure 7-4: Global - HPV Therapeutics Market (US$ Billion), 2016-2023
Figure 7-5: Global - Human Papillomavirus Infection Drug Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global - Human Papillomavirus Infection Drug Pipeline by Phase (Number), 2017 till 2023
Figure 7-7: Global – Active & Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (%), 2017 till 2023
Figure 7-8: Global – Active & Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Global - Favorable Parameters to Human Papilloma Virus Market Growth
Figure 8-2: Global - Challenges to Human Papilloma Virus Infection Development


Table 3-1: List of RNA Studies Targeting HPV E6 and E7
Table 3-2: Molecular Targeting HPV & Host Cellular Factors Interaction Using Natural & Herbal Derivatives


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ヒトパピローマウイルス(HPV)感染症治療薬の世界市場・治験インサイト(Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆